In addition to the genetic variation of CYP2D6 and CYP2E1 mentioned above that may increase the risk of anti-tuberculosis drug-induced liver injury (ATLI), hypermethylation of CYP2D6 and CYP2E1 may also increase the risk of liver injury induced by anti-TB drugs (Zhang et al., 2016; Wei et al., 2020). Here, CYP2E1 is linked to tuberculosis.